demethylzeylasteral Usage And Synthesis
Chemical Properties
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Tripterygium wilfordii.
Uses
Demethylzeylasteral is a natural product as new inhibitor to block the Bcl-XL-Bid interaction. Also, it is an immunosuppressive monomer isolated from the root xylem of Tripterygium wilfordii. It exhibits inhibition towards the glucuronidation elimination reaction of SN-38.
Definition
ChEBI: A carbopolycyclic compound with formula C29H36O6, originally isolated from Tripterygium wilfordii.
in vivo
Demethylzeylasteral (30 mg/kg, 6 times every 2 days, i.p.) inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis[1].
Demethylzeylasteral (4 mg/kg, 5 weeks, i.p.) inhibits the invasion of triple negative breast cancer by blocking classical and non classical TGF - β signaling pathways[2].
Demethylzeylasteral (30-120 mg/kg, 8 weeks, i.p.) improves inflammation in a unilateral ureteral obstruction rat model by inhibiting the activation of the NF - κ B pathway[4].
Demethylzeylasteral (10, 40 mg/kg, 30 days, i.g.) can alleviate atherosclerosis in AS rabbits[5].
Demethylzeylasteral (10, 20 mg/kg, 4 weeks, p.o.) improves CCl4 induced liver fibrosis in mice by inhibiting AGAP2 mediated FAK/AKT signaling[6].
| Animal Model: | Female nude mice modeled with glioma LN-229 cells[1]. |
| Dosage: | 30 mg/kg, 6 times every 2 days |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Reduced tumor volume |
| Animal Model: | Female BALB/c mice modeled with 4T1 cells[2]. |
| Dosage: | 4 mg/kg, 5 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Reduced cancer lung metastasis |
| Animal Model: | Rat model of unilateral ureteral obstruction[4]. |
| Dosage: | 30-120 mg/kg, 8 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited the increases in serum creatinine, blood urea nitrogen and Up/Ucr ratio |
| Animal Model: | Atherosclerotic rabbit[5]. |
| Dosage: | 10, 40 mg/kg, 30 days |
| Administration: | Intragastrical (i.g.) |
| Result: | Reduced blood lipids triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) |
| Animal Model: | CCl4-induced liver fibrosis model[6]. |
| Dosage: | 10, 20 mg/kg, 4 weeks |
| Administration: | Oral gavage (p.o.) |
| Result: | Inhibited the expression of TGF-β1 |